To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

For the quarterly period ended September 30, 2025 OR UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________to___________ Commission file number 001-39695 VIATRIS INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incor ...

技术访问问题 - 浏览器需启用Javascript和cookies以确保未来正常访问 [1] - 启用广告拦截插件可能导致访问被阻止 [1] - 需禁用广告拦截插件并刷新页面以继续 [1]

财务业绩概要 - 第三季度调整后每股收益为67美分 超出市场预期的63美分 但低于去年同期的75美分 [1] - 第三季度总营收为37.6亿美元 同比下降2% 但超出市场预期的36亿美元 [1] - 公司上调2025年全年业绩指引 总营收预期区间调整为139亿至143亿美元 调整后每股收益预期区间调整为2.25至2.35美元 [12] 分区域销售表现 - 发达市场销售额为22.5亿美元 同比下降5% 略超市场预期的22亿美元 [3] - 新兴市场销售额为5.704亿美元 同比增长7% 超出市场预期的5.5亿美元 [4] - 日本、澳大利亚和新西兰市场销售额为3.063亿美元 同比下降9% 超出市场预期的3.03亿美元 [4] - 大中华区销售额为6.152亿美元 同比增长9% 超出市场预期的5.79亿美元 [4] 分产品线销售表现 - 品牌药收入增长3%至24亿美元 主要得益于大中华区和新兴市场的强劲表现以及发达市场部分关键品牌的增长 [5] - 立普妥销售额达3.961亿美元 络活喜销售额增至1.797亿美元 优泌乐销售额增至1.572亿美元 乐瑞卡销售额降至1.265亿美元 [8] - 仿制药收入下降5%至13.1亿美元 主要受印度印多尔工厂收到FDA警告信和进口警报的影响 但北美部分复杂产品、欧洲关键市场及新兴市场的增长抵消了部分下滑 [9][10] 运营指标与资本回报 - 调整后毛利率为56% 低于去年同期的58.5% [10] - 年初至今已通过股息和股票回购向股东返还超过9.2亿美元资本 其中股票回购超过5亿美元 预计2025年全年股东回报将超过10亿美元 [11] 业务发展与管线进展 - 公司收购日本临床生物制药公司Aculys Pharma 获得pitolisant在日本的独家开发和商业化权利 计划就发作性睡病和阻塞性睡眠呼吸暂停综合征导致的日间过度嗜睡两个适应症在日本提交新药申请 [13] - 交易还包括在日本及亚太其他特定市场获得Spydia鼻喷雾剂的独家权利 该产品已于2025年6月在日本获批用于治疗癫痫持续状态 [14] - 已向FDA提交低剂量雌激素周效贴剂的新药申请 预计将于2026年年中获得批准 [14]

Viatris (NasdaqGS:VTRS) Q3 2025 Earnings Call November 06, 2025 08:30 AM ET Company ParticipantsCorinne Le Goff - Chief Commercial OfficerChris Schott - Managing DirectorBill Szablewski - Head of Capital MarketsNone - Company RepresentativeLes Sulewski - VP of Biotech Equity ResearchAsh Verma - Executive Director of SMID Biotech and BiopharmaNone - Company RepresentativeScott Smith - CEOPhilippe Martin - Chief R&D OfficerDoretta Mistras - CFOConference Call ParticipantsMatt Dellatorre - VP and Equity Analys ...

Viatris (NasdaqGS:VTRS) Q3 2025 Earnings Call November 06, 2025 08:30 AM ET Company ParticipantsCorinne Le Goff - Chief Commercial OfficerChris Schott - Managing DirectorBill Szablewski - Head of Capital MarketsNone - Company RepresentativeLes Sulewski - VP of Biotech Equity ResearchAsh Verma - Executive Director of SMID Biotech and BiopharmaNone - Company RepresentativeScott Smith - CEOPhilippe Martin - Chief R&D OfficerDoretta Mistras - CFOConference Call ParticipantsMatt Dellatorre - VP and Equity Analys ...

Viatris (NasdaqGS:VTRS) Q3 2025 Earnings Call November 06, 2025 08:30 AM ET Speaker1Good morning and welcome to the Viatris Q3 2025 earnings call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star then one on your touch-tone phone. To withdraw your question, please press star then two. Please ...

GAAP / Non-GAAP Reconciliations November 6, 2025 1 Operational change: Refers to constant currency percentage changes and is derived by translating amounts for the current period at prior year comparative period exchange rates and in doing so shows the percentage change from 2025 constant currency net sales, total revenues, adjusted EBITDA, and adjusted EPS to the corresponding amount in the prior year. This document contains proprietary information of Viatris Inc. Unauthorized use, duplication, disseminati ...

公司业绩表现 - 公司第三季度利润和营收超出市场预期 [1] - 业绩增长主要由其品牌药在中国和新兴市场的强劲需求所驱动 [1]

Viatris Reports Third Quarter 2025 Results and Updates 2025 Financial Guidance PITTSBURGH – November 6, 2025 – Viatris Inc. (Nasdaq: VTRS) today reported strong third quarter 2025 financial results and updated full-year financial guidance. Executive Commentary "We delivered another strong quarter by staying focused on our 2025 strategic priorities," said Scott A. Smith, Chief Executive Officer, Viatris. "Our performance this quarter reflects the continued strength of our execution across markets. We are adv ...